Reproductive health in SLE

Area of Science:

• Reproductive Endocrinology
• Immunology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) predominantly affects women, with estrogen metabolism abnormalities noted.
• Concerns about estrogen use in SLE stem from disease flares, murine models, and studies in patients with renal disease.
• Exogenous estrogens can offer benefits in specific clinical scenarios for both healthy women and those with SLE.

Purpose of the Study:

• To review the clinical applications of exogenous estrogens in women with SLE.
• To discuss the benefits and risks of estrogen therapy in various reproductive and menopausal contexts for SLE patients.
• To focus on birth control, assisted reproduction, and hormone replacement therapy.

Main Methods:

• Literature review of studies and clinical observations regarding estrogen use in SLE.
• Analysis of benefits and risks in pre-menopausal and post-menopausal women with SLE.
• Categorization of hormonal therapies including oral contraceptives, hormone replacement, and ovulation induction agents.

Main Results:

• Estrogens are generally contraindicated in SLE due to potential disease flares.
• Benefits include contraception, bone protection, fertility preservation (e.g., with cyclophosphamide), and management of menopausal symptoms (hot flashes, vaginal dryness).
• Estrogens may also play a role in preventing osteoporosis and potentially atherosclerosis in post-menopausal women.

Conclusions:

• While caution is warranted, exogenous estrogens can be beneficial for SLE patients in specific situations.
• Careful consideration of risks and benefits is crucial for personalized treatment strategies.
• Further research may clarify the role of estrogens in managing SLE comorbidities.